Abivax Shares Surge After Ulcerative Colitis Treatment Meets Primary Endpoint in Two Phase 3 Trials

MT Newswires Live
07-23

Abivax (ABVX) shares surged 553% in recent Wednesday trading after the company said its investigational ulcerative colitis drug candidate obefazimod met the primary endpoint of clinical remission in two global phase 3 trials.

The 50 mg once-daily dose of obefazimod achieved statistically significant remission at week 8 in both the Abtect-1 and Abtect-2 studies, meeting the FDA-defined benchmark for clinical success, the company said.

In Abtect-1, obefazimod delivered a placebo-adjusted remission rate of 19.3%, while Abtect-2 showed a 13.4% benefit over placebo. The drug also met all key secondary endpoints, including clinical response and endoscopic improvement.

The company said the treatment was well tolerated in both dose groups, with no new safety signals observed.

Abivax said it is conducting a 44-week maintenance study with results expected in Q2 2026 and plans to apply for US and EU approvals in H2 2026 if the results are positive.

Price: 65.30, Change: +55.30, Percent Change: +553.00

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10